. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced a strategic partnership with Advanced Rad Solutions (ARS) to place iCAD’s Xoft
Electronic Brachytherapy Systems
at ARS sites to treat patients diagnosed with non-melanoma skin cancer (NMSC). ARS is a full-service integrator of radiation therapies into treatment centers and physician practices.
As part of the strategic partnership, the Xoft
System will be used at each of ARS’ affiliated dermatology sites, beginning with its California sites, allowing patients to undergo electronic brachytherapy treatment in the convenience of a dermatologist’s office.
“We are pleased to provide patients with the most advanced treatment options for skin cancer in one integrated setting,” said Ken Ferry, iCAD’s CEO. “Our strategic partnership with ARS will enable us to treat more patients while expanding the number of systems we have in place, ultimately improving patient outcomes.”
“Electronic brachytherapy is an advanced, non-invasive procedure that can now be completed at the dermatologist’s office or in virtually any clinical setting under the supervision of a radiation oncologist,” said Stephen Doggett, M.D., Radiation Oncologist. “The on-site, real time collaboration of the dermatologist and radiation oncologist both at the time of treatment planning and in the treatment suite means improved outcomes and optimal management of skin reactions. Patients are very pleased with this multidisciplinary approach. By allowing providers and patients expanded access to this proven treatment in their dermatologist’s office where they received the diagnosis, there is a higher probability that patients will continue with their course of treatment and ongoing care.”
“We believe this strategic partnership will change the way skin cancer patients are treated by bringing the portable electronic brachytherapy technology to the dermatologist’s office through collaboration with radiation oncology,” said Steven Carrales, ARS President and CEO. “We now can offer patients a non-invasive alternative with compelling clinical outcomes. Additionally, by treating skin cancer patients in-house, we will reduce and potentially eliminate the need for patients to see multiple physicians at various locations, while ensuring that patients complete a full course of radiation.”